A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus

Table 1 Clinical and demographic features of the study subjects, as well as pharmacological treatments in patients with systemic lupus erythematosus

	Patients with SLE (n = 80), n (%)
Clinical parameters
Female/male	71/9
Age, years, mean ± SD	44 ± 11.9
Disease duration, months^a	139 ± 100
SLEDAI-2 K score, mean ± SD	4 ± 4.3
SDI, mean ± SD	0.8 ± 1.2
Disease activity patterns
CQD	46 (57.5 %)
CAD	18 (22.5 %)
MDA	14 (17.5 %)
RRD	2 (2.5 %)
Serological parameters
aPL (aCL, β₂-GPI, and/or LA)	39 (48.75 %)
ENA	48 (60 %)
Hypocomplementemia	53 (62.2 %)
Anti-dsDNA antibody, ongoing/previous	41 (51.2 %)/17 (21.1 %)
Treatments
Corticosteroids, 2.5 up to 12.5 mg/day	67 (83.7 %)
Hydroxychloroquine, 200 mg/day	48 (60 %)
Ongoing immunosuppressant therapy	25 (31.2 %)
Mycophenolate mofetil	11 (13.7 %)
Cyclosporine A	4 (5 %)
Azathioprine	5 (6.2 %)
Methotrexate, 10–15 mg/week	3 (3.7 %)
Thalidomide	1 (1.2 %)
IVIg	1 (1.2 %)
PEX	1 (1.2 %)
Anticoagulants	11 (13.7)
Antiaggregant	33 (41.25)

Abbreviations: SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, CQD clinical quiescent disease, MDA minimal disease activity, CAD chronic active disease, RRD relapsing-remitting disease, aPL antiphospholipid antibodies, aCL anticardiolipin antibodies, LA lupus anticoagulant, β ₂ -GPI β₂-glycoprotein I antibodies, ENA extractable nuclear antigen antibodies, PEX plasma exchange, IVIg intravenous immunoglobulin, anti-dsDNA anti-double-stranded DNA
^aDisease duration at the time of sample collection

ISSN: 1478-6362